Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AP301

Phase 3Small molecule

AAlebund Pharmaceuticals

AP301 is one of 52 small molecule programs targeting Acute Lung Injury. It is currently in Phase 3.

2

Indications

4

Total Trials

1

Active Trials

51

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lung InjuryActive, not recruiting

HyperphosphatemiaActive, not recruiting

Acute Lung InjuryPhase 2

Active, not recruiting

HyperphosphatemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Acute Lung Injury

#DrugCompanyPhaseTrials

Gleevec

Kalydeco

Vertex Pharmaceuticals

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Pitressin

AAultman Health Foundation

Esbriet

LLegacy Health System

Neo-Synephrine

EExela Pharma Sciences, LLC.

Oxbryta

GGlobal Blood Therapeutics

Adrenaline

SSamson Clinical Operations Pty Ltd

Ultomiris

Heparin Sodium

BBaxter Healthcare Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Hyperphosphatemia

NCT06933472

Clinical

Trials by Indication[1]

Hyperphosphatemia2 trials

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Recruiting·AAlebund Pharmaceuticals·Phase 3·NCT06933472·264 enrolled

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

Completed·AAlebund Pharmaceuticals·Phase 3·NCT07030595·474 enrolled

Acute Lung Injury1 trial

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Completed·AApeptico Forschung und Entwicklung GmbH·Phase 2·NCT01627613·40 enrolled

Unspecified1 trial

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

Completed·AAlebund Pty Ltd·Phase 1·NCT06100627·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AP301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alebund Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlebund Pharmaceuticals

Related News